Phase I safety and immunogenicity evaluations of an alphavirus replicon HIV-1 subtype C gag vaccine in healthy HIV-1-uninfected adults.
about
A mouse model for Betacoronavirus subgroup 2c using a bat coronavirus strain HKU5 variantDevelopments in HIV-1 immunotherapy and therapeutic vaccination.Novel directions in HIV-1 vaccines revealed from clinical trialsNonreplicating vectors in HIV vaccines.Role of humoral versus cellular responses induced by a protective dengue vaccine candidate.Use of placebos in Phase 1 preventive HIV vaccine clinical trialsEvaluation of serologic and antigenic relationships between middle eastern respiratory syndrome coronavirus and other coronaviruses to develop vaccine platforms for the rapid response to emerging coronaviruses.Development of chimpanzee adenoviruses as vaccine vectors: challenges and successes emerging from clinical trials.Self-replicating alphavirus RNA vaccines.RNA-based viral vectors.New developments in an old strategy: heterologous vector primes and envelope protein boosts in HIV vaccine design.Alphavirus Replicon DNA Vectors Expressing Ebola GP and VP40 Antigens Induce Humoral and Cellular Immune Responses in Mice.
P2860
Q30360627-D516E713-7A7D-4C8C-AED0-49C4E196A0EFQ30364312-38678B3C-2EB0-43DE-BC96-9CDF8E9FD55BQ33645528-0258F666-D2EE-441C-B32F-2D6C5988CDFAQ33693891-716AD0CA-6EF3-4699-9D1B-D1A235869F87Q35034240-AD2184E9-5EA3-41E9-8371-6F9A416AAAA2Q36011214-C3FA1883-5CC6-426C-A9B8-07B93BF02D36Q37635133-26B91887-BBE5-4EE1-9182-5C67355509F2Q38096490-04B49E9F-C0E4-4422-9D60-90DFB5D8CE81Q38255634-091CD6D6-7B83-470A-984F-88A9574D09B7Q38266413-E13D0A30-09E7-47DF-B62F-17F9313936E3Q38748193-D2B43901-7584-4E2A-829E-A5C78C1928F3Q47548508-78085F53-B6EA-4644-A6D6-1240CB14A008
P2860
Phase I safety and immunogenicity evaluations of an alphavirus replicon HIV-1 subtype C gag vaccine in healthy HIV-1-uninfected adults.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh
2012年學術文章
@zh-hant
name
Phase I safety and immunogenic ...... althy HIV-1-uninfected adults.
@ast
Phase I safety and immunogenic ...... althy HIV-1-uninfected adults.
@en
type
label
Phase I safety and immunogenic ...... althy HIV-1-uninfected adults.
@ast
Phase I safety and immunogenic ...... althy HIV-1-uninfected adults.
@en
prefLabel
Phase I safety and immunogenic ...... althy HIV-1-uninfected adults.
@ast
Phase I safety and immunogenic ...... althy HIV-1-uninfected adults.
@en
P2093
P2860
P356
P1476
Phase I safety and immunogenic ...... althy HIV-1-uninfected adults.
@en
P2093
HVTN 040/059 Protocol Team
M Pensiero
NIAID HIV Vaccine Trials Network
S S Abdool Karim
P2860
P304
P356
10.1128/CVI.00258-12
P50
P577
2012-08-22T00:00:00Z